Haidan Chen

Dr. Haidan Chen

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2016 in HLA
Verified
Journal Article
Closed access
PDF file
CFC. Fu
C. Fu
HZH. Zhao
H. Zhao
YWY. Wang
Y. Wang
HCH. Cai
H. Cai
YXY. Xiao
Y. Xiao
HCHaidan Chen
Haidan Chen

28 November 2023 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
XYXiang Yu
Xiang Yu
SJSiyu Jia
Siyu Jia
SYShi Yu
Shi Yu
YCYaohui Chen
Yaohui Chen
CZChengwei Zhang
Chengwei Zhang
YDYanfeng Dai
Yanfeng Dai
As a naturally occurring cytolytic peptide, melittin (MLT) not only exhibits a potent direct tumor cell-killing effect but also possesses various immunomodulatory functions. MLT shows minimal chances for developing resistance and has been recognized as a promising broad-spectrum antitumor drug because of this unique dual mechanism of action. However, MLT still displays obvious toxic side effects during treatment, such as nonspecific cytolytic activity, hemolytic toxicity, coagulation disorders, and allergic reactions, seriously hampering its broad clinical applications. With thorough research on antitumor mechanisms and the rapid development of nanotechnology, significant effort has been devoted to shielding against toxicity and achieving tumor-directed drug delivery to improve the therapeutic efficacy of MLT. Herein, we mainly summarize the potential antitumor mechanisms of MLT and recent progress in the targeted delivery strategies for tumor therapy, such as passive targeting, active targeting and stimulus-responsive targeting. Additionally, we also highlight the prospects and challenges of realizing the full potential of MLT in the field of tumor therapy. By exploring the antitumor molecular mechanisms and delivery strategies of MLT, this comprehensive review may inspire new ideas for tumor multimechanism synergistic therapy.

13 January 2025 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
SJSiyu Jia
Siyu Jia
YCYaohui Chen
Yaohui Chen
CZCan Zhuo
Can Zhuo
MHMing Hu
Ming Hu
CZChengwei Zhang
Chengwei Zhang
XYXiang Yu
Xiang Yu

26 November 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
SZShuailong Zhao
Shuailong Zhao
CFCegang Fu
Cegang Fu
BGBoya Gong
Boya Gong
HWHongyan Wu
Hongyan Wu
RZRuitao Zhang
Ruitao Zhang
HCHaidan Chen
Haidan Chen
Background: Abnormal protein glycosylation is a key feature of tumors. Among the modifications, Tn antigen (GalNAcα1-Ser/Thr) and its sialylated derivative, STn antigen (Neu5Acα2-6GalNAcα1-O-Ser/Thr), are prominent tumor-associated carbohydrate antigens. These antigens exhibit abnormal accumulation in epithelial malignancies, including colorectal cancer, breast cancer, and pancreatic cancer. Their pathological overexpression primarily stems from inactivation of the COSMC/T-synthase axis, either due to genetic mutations or epigenetic silencing, leading to truncated O-glycan biosynthesis. Findings: Tn/STn antigens directly promote tumor progression by activating oncogenic signaling pathways (e.g., EGFR/FAK) and inducing epithelial-mesenchymal transition. Additionally, these antigens play a noticeable role in immune suppression in the tumor microenvironment. Tn antigens bind to macrophage galactose-specific lectin (MGL) on myeloid cells, while STn antigens interact with sialic acid-binding immunoglobulin-like lectins (Siglecs), collectively inhibiting natural killer cell cytotoxicity, dendritic cell maturation, and T cell activation. Changes in serum levels of glycoprotein tumor markers (e.g., CA15–3 and CA125) are associated with aberrant protein glycosylation in cancer cells, which may influence their expression levels, stability, or immunodetection. Current therapeutic approaches include monoclonal antibodies (e.g., Remab6, L2A5), antibody-drug conjugates, CAR-T cell therapies, and vaccines. However, challenges remain due to glycan heterogeneity and low immunogenicity. Conclusion: Tn/STn antigens play a pivotal role in tumorigenesis and immune evasion, presenting significant potential for both diagnostic and therapeutic applications. Future research should concentrate on elucidating the underlying mechanisms, developing innovative detection technologies, and promoting multidisciplinary collaborations to advance Tn/STn antigen-based tumor molecular subtyping, precision targeted therapies, and efficacy prediction systems, thereby providing new directions for cancer diagnosis and treatment.

1 April 2026 in Clinical Interventions in Aging
Verified
Journal Article
Open access
PDF file
HZHang Zhang
Hang Zhang
HCHuili Cai
Huili Cai
YCYunzhong Cheng
Yunzhong Cheng
XLXuelin Li
Xuelin Li
YLYang Liu
Yang Liu
HCHaidan Chen
Haidan Chen
Background: Surgical management of lumbar degenerative diseases (LDD) in octogenarians requires balancing effective neural decompression against diminishing physiological reserves. While general anesthesia (GA)-based endoscopic techniques (ENDO-GA) are highly effective, they often impose excessive systemic stress on frail patients. Conversely, percutaneous endoscopic lumbar discectomy under local anesthesia (PELD-LA) provides targeted decompression while mitigating these GA-associated risks. Given the scarcity of direct comparisons in this fragile population, this study evaluates the safety and efficacy of PELD-LA versus ENDO-GA. Methods: We retrospectively analyzed 100 consecutive octogenarians treated for LDD between January 2021 and December 2024. Patients were stratified into two specific surgical strategy groups: targeted decompression via PELD-LA (n=54) and extensive decompression via ENDO-GA (utilizing UBE or Delta techniques, n=46). To minimize selection bias, a 1:1 Propensity Score Matching (PSM) was conducted using specific covariates (age, sex, comorbidities, and ASA classification), yielding 39 matched pairs (n=78). Primary outcomes assessed perioperative safety and recovery efficiency (complications, PONV, ambulation time, and length of hospital stay).Secondary outcomes evaluated postoperative clinical efficacy (VAS and ODI at 3 months, and modified MacNab criteria at 12 months postoperatively). Results: After propensity score matching, baseline characteristics were well-balanced between the two groups. Perioperatively, the PELD-LA group exhibited significantly shorter operative times (97 vs 150 min, P< 0.001), earlier ambulation (48 vs 72 h, P< 0.001), and reduced length of hospital stay (9 vs 14 days, P< 0.001) compared to the ENDO-GA group. Clinically, despite a smaller “targeted” decompression range, PELD-LA achieved long-term efficacy (MacNab criteria: 94.9% vs 94.9%, P=1.000) comparable to extensive decompression, while demonstrating superior early pain relief and functional improvement (VAS and ODI) at 3 months postoperatively (P< 0.01). Crucially, the overall complication rate was significantly lower in the PELD-LA group (30.8% vs 82.1%, P< 0.001), primarily driven by a marked reduction in postoperative nausea and vomiting (PONV) (23.1% vs 66.7%, P< 0.001). Conclusion: Within our short-to-medium-term observation period, PELD-LA delivered clinical efficacy comparable to GA-based endoscopic procedures for octogenarians, while significantly reducing perioperative complications and accelerating recovery. Crucially, we do not assert that PELD-LA is universally superior; rather, we emphasize the importance of tailored patient selection. For frail patients with limited physiological reserve, PELD-LA serves as a physiologically rational strategy, balancing targeted decompression with the preservation of systemic stability.

27 August 2024 in Journal of Orthopaedic Surgery and Research
Verified
Journal Article
Open access
PDF file
SCShiwen Chen
Shiwen Chen
DYDiao Yang
Diao Yang
CZCan Zhuo
Can Zhuo
ZZZhenyu Zhou
Zhenyu Zhou
HAHamza Bin Aleem
Hamza Bin Aleem
HCHaidan Chen
Haidan Chen
This study analyzes the safety and efficacy of percutaneous vertebroplasty (PVP) and percutaneous kyphoplasty (PKP) treatments for Stage III Kummell’s disease without neurological symptoms, comparing the advantages and disadvantages of these two minimally invasive surgical methods. A retrospective analysis was conducted on 53 patients with non-neurological Stage III Kummell’s disease treated with PVP and PKP at our hospital from December 2018 to January 2023. Patients were divided into PVP (25 cases) and PKP (28 cases) groups based on the surgical method. There were no significant differences in general preoperative data between the two groups (all p > 0.05), ensuring comparability. The study compared surgical duration, volume of bone cement injected, distribution pattern of bone cement, rate of bone cement leakage, and preoperative, postoperative, and final follow-up scores of Visual analogue scale(VAS) and Oswestry disability index(ODI). Additionally, relative anterior height of the injured vertebrae, and Cobb angle of deformity, along with their changes at preoperative, postoperative, and final follow-up stages were calculated and analyzed. No significant preoperative differences were observed between the groups (p > 0.05). The PKP group had longer surgeries, higher cement volumes (p < 0.001), and lower leakage rates (p < 0.05), with primarily chunky cement distributions versus mixed distributions in the PVP group. No complications other than cement leakage occurred. VAS and ODI scores showed no significant changes at various time points (p > 0.05) but improved significantly from preoperative (p < 0.001). Both groups saw improved vertebral heights and Cobb angles post-surgery (p < 0.05), with more significant improvements in the PKP group (p < 0.05). Over time, both groups experienced gradual vertebral height loss and increased Cobb angles, more pronounced in the PKP group (p < 0.05). At the final follow-up, there were no statistical differences in vertebral height and Cobb angle between the two groups (p > 0.05). The study evaluates the safety and efficacy of PVP and PKP for Stage III Kummell’s disease without neurological symptoms, comparing the merits of both minimally invasive techniques.